Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is an increased risk of opportunistic infections in patients with PsA, and this risk is increased further with targeted biologic therapy.<b>Areas covered</b>: This paper reviews the role of the interleukin (IL)-12, IL-23 and IL-17 axis in the pathogenesis of PsA.
|
31847608 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-17A+ CD8+ T cells were predominantly TCRαβ+ and their frequencies were increased in the SF vs. PB of patients with established PsA (p<0.0001) or other SpA (p=0.0009).
|
31677365 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, these cells likely to be a part of the IL-23/IL-17A cytokine network and play a critical role in the pathogenesis of PsA.
|
31541902 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the high cost of IL-17 inhibitors presently prevents their use in disease states other than psoriasis or psoriatic arthritis.
|
31402691 |
2020 |
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Relative to TNF and IL-17, IL-12/23 inhibitors were associated with a reduced risk of serious infection in biologic-naïve patients with PsO or PsA.
|
31672774 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biologic agents with different mechanisms of action [inhibitors of tumor necrosis factor-α (TNF-α), interleukin (IL)-12/23, and IL-17] showed efficacy in randomized controlled trials (RCT) in the treatment of psoriatic arthritis.
|
30824641 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since the connection of dysregulated IL-17 and psoriasis pathogenesis turned out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been approved and are used as first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in clinical development.
|
31727784 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti-Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL-23/IL-17 pathway often provide prolonged, deep responses and in some cases even remission (3).
|
31736273 |
2020 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-17 (IL-17) is an important cytokine involved in the pathogenesis of bone lesions of psoriatic arthritis (PsA).
|
30418122 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that Breg cells are a major target of apremilast in PsA and psoriasis and that apremilast-induced increase of Breg cells is associated with a decrease of Th1 cells, IFNγ-producing NKT cells and IL-17-producing NKT cells.
|
31209492 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib).
|
30499259 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib).
|
30499246 |
2019 |
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
83 records were enrolled.The IL-17 level was elevated in AS (SMD = 2.348, P < .001), RA (SMD = 1.502, P < .001), PsA (SMD = 1.710, P < .001) and OA (SMD = 1.192, P = .016), and similar results occurred in subgroup analysis.
|
31271739 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent introduction of antibodies blocking IL-17 has expanded the therapeutic options for SpA, as well as psoriasis and psoriatic arthritis.
|
30941119 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two independent authors searched the databases PubMed and EMBASE for studies reporting on adverse events in phase 3 trials of IL-17 and IL-23 inhibitors for patients with psoriasis and psoriatic arthritis.
|
31721310 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we focus on the latest data from studies investigating the role of IL-17A in ankylosing spondylitis (AS) and PsA that build on existing and emerging scientific knowledge in the field.
|
31278139 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA.
|
30891646 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokines from the IL-17 family have been shown to be involved in the pathogenesis of several diseases such as spondyloarthritis, psoriatic arthritis, or psoriasis.
|
31485194 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, although targeting the IL-23-IL-17 axis substantially improves psoriasis outcomes, this strategy is not more effective than TNF inhibitors in improving musculoskeletal symptoms in PsA.
|
30742092 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-17A is classically considered to be the most biologically active, but recent studies have shown that IL-17F is also increased in psoriatic skin and synovial cell in psoriatic arthritis, supporting the rationale for targeting both IL-17A and IL-17F in psoriatic disease.
|
31172372 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the circulation, we found increased percentage of CD8<sup>+</sup> CCR6<sup>+</sup> T cell effectors expressing CD69 and of IL-17-producing T cells in patients with psoriatic arthritis.
|
31350460 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriasis and PsA, some are already in the therapeutic armamentarium and others are in the development.
|
31447673 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis.
|
30376130 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the short-term effects of tumor necrosis factor alpha (TNF-α) and interleukin-17A (IL-17A) inhibition on the structural changes in psoriatic arthritis (PsA) using high-resolution peripheral quantitative computed tomography (HR-pQCT) have been reported, no studies have investigated the long-term structural changes in PsA patients receiving routine care.
|
31801610 |
2019 |
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
SPIRIT-P1 and SPIRIT-P2 are phase 3 trials investigating ixekizumab, an interleukin-17A antagonist, in the treatment of patients with active PsA.
|
31113794 |
2019 |